Takeda will be investing approximately $30 billion into its U.S. operations over the next five years, the company announced.

Takeda was scrambling to accommodate for rapidly sinking profits from the hasty decline of ADHD mainstay Vyvanse with a 140 ...

Takeda forecast annual operating profit to rise 39% to Y475.00 billion. It expects savings from its enterprise-wide efficiency program, significant declines in restructuring expenses and lower ...

The lawsuits pertain to the drug Dexilant, used to treat acid reflux, and Copaxone, an injectable drug that treats a type of ...

Andrew Mckibben; IR Contact Officer; Mirum Pharmaceuticals Inc. Christopher Peetz; Chief Executive Officer, Co-Founder, Director; Mirum Pharmaceuticals Inc. Peter Ra ...

The leading Merkel Cell Carcinoma Companies such as ImmunityBio, OncoSec Medical, Exelixis, 4SC, Kartos Therapeutics, Incyte ...

Takeda has shot down candidates acquired in its $525 million Maverick Therapeutics takeover, blowing a hole in its oncology R ...

Takeda’s Julie Kim argues that Trump’s idea to match drug prices to that of other countries could cost the industry up to $1 ...

Afatinib has broad activity against EGFR mutations. However, the approval for uncommon mutations was based on data from 38 ...

Novavax, Inc. (Nasdaq: NVAX) today announced its financial results and operational highlights for the first quarter ended ...

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...